We must allow Medicare to negotiate drug prices with pharmaceutical companies.
Allow Medicare to negotiate drug prices with pharmaceutical companies.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
“We must allow Medicare to negotiate drug prices with pharmaceutical companies.”
legacy_unverified · Source version not recorded · locator unknown
The IRA creates a new Drug Price Negotiation Program requiring the Secretary of HHS to negotiate prices for certain qualifying single-source drugs furnished to Medicare beneficiaries.
legacy_unverified · Source version not recorded · locator unknown
Sponsor: Rep. McGarvey, Morgan [D-KY-3] (Introduced 06/25/2025). This bill eliminates cost-sharing for generic drugs for those with the lowest-income under the Medicare prescription drug benefit's Low-Income Subsidy Program beginning in 2026.
legacy_unverified · Source version not recorded · locator unknown
CMS states that on January 1, 2026, new negotiated maximum fair prices under the Medicare Drug Price Negotiation Program went into effect, and the Medicare Transaction Facilitator began operations to support manufacturer effectuation of those prices.
legacy_unverified · Source version not recorded · locator unknown
CMS says it issued proposed rulemaking for the Medicare Drug Price Negotiation Program on June 12, 2026, with comments closing August 17, 2026, and issued July 16, 2026 draft guidance on effectuation of maximum fair prices for the 2028 negotiation cycle.
Assessments
Medicare drug-price negotiation was enacted federally through the Inflation Reduction Act and CMS records show negotiated prices took effect nationally on January 1, 2026. That satisfies the promised policy outcome. McGarvey is not shown to have been a principal cause of the 2022 enactment, which predated his House service, but the program was implemented while he was serving in federal office and he has shown related prescription-drug affordability effort.
Medicare drug-price negotiation was enacted nationally through the Inflation Reduction Act in 2022, before Morgan McGarvey entered Congress in January 2023 and before the cited 2024 campaign promise. Because the promised policy outcome existed, but was completed by other federal officials with no shown McGarvey contribution, this should not be credited as fully delivered by him. His later Cutting Copays Act shows related prescription-drug affordability effort, but it did not enact or materially advance Medicare negotiation authority.
The promised policy outcome, allowing Medicare to negotiate drug prices with pharmaceutical companies, was enacted nationally through the Inflation Reduction Act's Medicare Drug Price Negotiation Program before McGarvey's current congressional service. McGarvey later introduced related drug-affordability legislation, but that bill addressed generic drug cost-sharing rather than creating or expanding Medicare negotiation authority. Because the core promised outcome exists in federal law, the promise is best rated delivered, though the timing is not attributable to his same or later term.